I'm LongbridgeAI, I can summarize articles.SYNGAP1, a rare neurological disorder with no approved therapies, is the focus of an upcoming phase I trial authorized in multiple countries and set to begin in Q4. The multi-cohort study uses preclinical and natural history data, with endpoints in cognitive, motor, and seizure domains. Analyst Day will provide further trial and pipeline updates.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
SYNGAP1, a rare neurological disorder with no approved therapies, is the focus of an upcoming phase I trial authorized in multiple countries and set to begin in Q4. The multi-cohort study uses preclinical and natural history data, with endpoints in cognitive, motor, and seizure domains. Analyst Day will provide further trial and pipeline updates.
Based on